Horsholm, Denmark, September 20, 2016 – Today, ExpreS2ion Biotech Holding AB
(“ExpreS2ion”), and VaxInnate Corporation (“VaxInnate”) announce that they have
signed a Research License Agreement under which VaxInnate can conduct vaccine
research and preclinical development based on ExpreS2ion’s patented ExpreS2
-platform for a year.
The Research License Agreement
VaxInnate has decided to continue its proprietary vaccine research with ExpreS2,
which was initiated under a simple Material Transfer and Use Agreement (“MTA”)
in 2015, under a new Research License Agreement (“RLA”). The RLA grants
VaxInnate the right to conduct research based on ExpreS2 for one year, until
August 2017. The agreement has no immediate significant financial impact on
ExpreS2ion, but it has the potential for future revenues from new commercial
licenses, if VaxInnate bring products based on the ExpreS2-platform into
clinical development. Furthermore, this expands the use and demonstrates the
functionality of the ExpreS2-platform.
About VaxInnate
VaxInnate Corporation is a privately-held biotechnology company in Cranbury, NJ,
USA, that is pioneering breakthrough technology for use in developing novel
vaccines. Its vaccine platform is based on Toll-like receptor (TLR) technology,
which dramatically improves vaccine immunogenicity and efficacy. The technology
involves genetically fusing vaccine antigens to the bacterial protein flagellin,
a potent stimulator of the innate immune system. VaxInnate’s current focus is on
vaccines for infectious diseases, including seasonal and pandemic flu, RSV,
dengue and Zika.
Steen Klysner, CEO, ExpreS2ion, comments
“We are pleased that an accomplished partner as VaxInnate wishes to continue
their vaccine research with our proprietary ExpreS2 platform. The combination of
Vaccinates proprietary vaccine technology and our platform enable efficient
development of new and exciting products and we look forward to the results ”
Certified Advisor
Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.
For further information, please contact:
Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com
This information is information that ExpreS2ion is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out above on September
20, 2016, at 12.00 CET.
About ExpreS2ion
ExpreS2ion Biotech Holding AB, with company register number 559033-3729, has
through the wholly owned Danish subsidiary ExpreS2ion Biotechnologies ApS,
developed a platform technology enabling cost effective and robust production of
complex proteins for the development of vaccines and diagnostics for e.g.
Malaria and Zika. Since foundation in 2010, the subsidiary has used its patented
ExpreS2 platform to produce more than 200 proteins in collaboration with
research institutions and biopharmaceutical companies, with an efficiency and
success rate superior to competing technologies.
